Trial Profile
An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE(R)), Abacavir and Amprenavir in HIV-1 Infected NNRTI Naive Adults
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary) ; Abacavir; Amprenavir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 13 Jul 2014 New trial record